Beamtree Holdings Limited Overview
Beamtree is an Australian healthcare-software micro-cap that sells AI-enabled decision-support, clinical-coding and benchmarking tools to hospitals, health systems and pathology laboratories. Its origins lie in Ripple-Down Rules, a knowledge-acquisition technique developed at UNSW and commercialised since 1996 as RippleDown, which automates the interpretation of laboratory results in more than 25 countries. Through the 2020 Pavilion Health and 2021 Potential(x) acquisitions, it added clinical-coding audit software (PICQ, RISQ) and the operating contract for The Health Roundtable, the main hospital benchmarking cooperative in Australia and New Zealand. FY26 revenue was A$29.2m, about 94% recurring, but growth has slowed to low single digits overall. The company sits at an inflection point. A 2026 strategic review exited non-core products and wrote down A$13.1m of intangibles. A new CEO from TechnologyOne was appointed in July 2026. Lender covenants were reset after a growth-covenant breach. The investment case now rests on commercialising autonomous coding and international expansion with a thin cash buffer.
What the company does
Beamtree sells software and data services that turn coded healthcare data into decisions and automation. Its FY26 investor update describes the business as combining clinical, coding and data expertise with AI to help hospitals and pathology labs improve clinical quality, coding accuracy and reimbursement. The company stresses that its proprietary platforms are co-developed with customers and embedded in live workflows (FY26 Full-Year Investor Update, 28 Aug 2026).
The FY26 Annual Report gives the principal activity as AI-based decision support, data-insight solutions and other software services to the healthcare industry. It cites more than 193 end customers in 25 countries (FY26 Directors' Report). The FY26 investor presentation gives a broader figure of ~400 customers across 1,200+ locations in ~25 countries; the gap probably reflects counting member hospitals and sites rather than contracting entities (discrepancy noted).
Business lines (FY26 presentation framing)
| Business line | FY26 share of revenue | What it does | Key products |
|---|---|---|---|
| Analytics (Knowledge Networks) | 42% | Hospital and health-system benchmarking and peer analytics | Health Roundtable platform, Evolve (UK) |
| Coding (Coding Assistance & Data Quality) | 30% | Audit and assurance of clinically coded hospital episodes; coding automation | PICQ, PICQ Audit, RISQ, ACS, ICP |
| Diagnostics | 28% | Rules-based automation of lab result interpretation and reporting | RippleDown Expert, RippleDown Auditor |
Source: FY26 Results Investor Presentation. Clinical Decision Support, a fourth statutory segment, was discontinued during FY26.
Business and revenue model
Recurring revenue (94% of FY26 revenue, A$27.5m): licence, subscription and usage fees. Usage-based RippleDown contracts charge per interpretation or a fixed periodic fee. PICQ and RISQ are licensed by subscription, with indicative pricing per coded episode. Health Roundtable revenue comes from a long-term operating contract with the cooperative, extended to July 2031 in FY23.
Non-recurring revenue (6%, A$1.6m): consulting, data-quality audits (for example, national audits in Saudi Arabia and Singapore), rule-building and implementation services. This fell 54% in FY26 as the company moved away from one-off audit projects.
Channel mix (FY26): Direct customers A$26.9m (92%); global partners A$2.3m (8%, mainly the Abbott diagnostics co-sell and licence relationship) (FY26 Annual Report, Note 4).
Revenue timing: Most revenue is recognised over time. In FY25, A$24.9m was recognised over time and A$3.7m at a point in time.
Mix characterisation: Roughly 94% subscription/licence/usage, 6% services. The model is close to SaaS, but some revenue is quasi-licence (on-premise RippleDown deployments) and some is cooperative-operator revenue (Health Roundtable).
Value-chain position and customers
Beamtree sits in the health-information middle layer. It does not own the electronic medical record (EMR) or the laboratory information system (LIS). Instead it consumes coded data from those systems and returns interpretations, audit findings, coding corrections and benchmarks.
Hospitals and health systems: public health districts, state health departments, private operators such as Healthscope, Ramsay and St Vincent's (historic contracts), NHS trusts, Canadian provincial systems, and Saudi insurers and hospital groups.
Pathology laboratories: public and private labs including ACT Pathology, Healthscope NZ, Ampath (South Africa, A$10.1m five-year contract in 2022) and NHS labs.
Government and payers: Saudi Center for National Health Insurance (CNHI), Singapore Ministry of Health, IHACPA-adjacent funding environments.
Benchmarking members: 189 member hospitals of The Health Roundtable, covering about 80% of acute activity across ANZ (FY26 presentation).
Company self-description vs. independent characterisation
Company description (paraphrased from the FY26 Annual Report and presentation): A leading healthcare technology company focused on AI-enhanced solutions for coded data in hospital and pathology markets. Its four product segments are Diagnostic Technology, Clinical Decision Support, Coding Assistance & Data Quality, and Analytics & Knowledge Networks. The company says it processes 73% of acute patient records in Australia and interprets more than 100m cases a year through RippleDown.
Independent characterisation: Beamtree is a sub-scale (A$29m revenue) roll-up of three niche healthcare-data businesses: PKS/RippleDown, Pavilion/PICQ and Potential(x)/Health Roundtable. Each holds a defensible, sticky domestic niche with low churn (renewals above 95%) but a modest growth ceiling. Repeated attempts to turn this into a high-growth AI platform have not yet delivered. These include the A$60m ARR target by end-2026, international expansion, and autonomous coding. ARR grew from A$22.8m (FY23) to about A$27m (FY26), and the FY26 accounts recorded goodwill impairments that formally lowered long-term growth assumptions. The business is best described as a low-growth, high-retention vertical software company running near operating breakeven, with venture-style optionality in autonomous coding.
Strategy
Stated strategy (latest annual report and investor materials, paraphrased)
The FY26 strategic review set five themes: a refined product mix, a reshaped cost base, tighter capital allocation, sharper sales execution, and a stronger executive team. It also simplified the organisation and clarified accountabilities.
Investment is now concentrated on the products management judges to have the strongest customer resonance, margin potential and capacity for innovation:
-
Diagnostics — RippleDown.
-
Coding — PICQ, PICQ Audit and RISQ.
-
Analytics — the Health Roundtable platform and UK Evolve.
New launches in FY27: the Autonomous Coding Solution (ACS) and Autonomous Data Entry (ADE), both with selected customers.
FY27 priorities per the FY26 presentation: execution and focus; using the IP to create value for partners; and continued ARR growth from established and new products. Cost growth is targeted to stay below revenue growth (FY26 Directors' Report).
Strategic initiatives in the last 24 months
| Initiative | Date | Description | Status / targets |
|---|---|---|---|
| Strategic review | Announced Feb 2026; interim update 5 May 2026; completed Aug 2026 | Product prioritisation, cost reset, capital discipline, leadership renewal | Completed; exited Ability and Wellness Roundtables; ADI wind-down; ICP development paused |
| Cost reset | Mar–Jun 2026 | Board action to reset the cost base toward breakeven; directors take fees in equity | FY27: cost growth below revenue growth |
| Autonomous Coding Solution | Pilots FY25–FY26 in Australia, UK, Canada; launch FY27 | "No-touch" AI coding; indicative pricing 6–8x current per-episode pricing | FY25 roadmap: MVP and commercial model in FY26, scale FY27–FY28, become a "one-stop shop" for coding by FY29+ |
| Integrated Coding Platform with Lean | Partnership Oct 2023; implementation FY25 | Assisted-coding platform for Saudi Arabia | Development ceased FY26 pending product/market fit; capitalised costs impaired |
| PICQ Audit | Launched FY25 | Audit-plus-analytics module for funding recovery | >20 clients, >A$1m ARR; drove 23% PICQ growth in FY25 |
| Evolve (UK) with NHS Confederation | Agreement FY25; ~A$2m investment 1H FY26 | Next-gen NHS benchmarking platform modelled on the Health Roundtable | Commercial uptake not yet disclosed |
| Saudi Arabia expansion | 2024–2026 | CNHI PICQ licence (A$1.4m), Fakeeh Care Group (A$2m, May 2026), health-information strategy work | Ongoing |
| Singapore | Aug 2025 | A$1m Ministry of Health clinical coding audit contract | Delivering |
| Information security | Completed 2025 | ISO 27001 certification; Information Security Management framework; two FTE cyber staff | Completed |
| Debt facility restructure | 20 Aug 2026 | Growth covenant replaced by revenue, cash-profit and liquidity covenants | First test 30 Sep 2026 |
Medium-term targets and guidance history
| Date | Target / guidance | Outcome |
|---|---|---|
| FY23 results (Aug 2023) | Revenue growth ~+20% for FY24 | FY24 revenue +21% (achieved) |
| Oct 2024 / Nov 2024 | ARR of A$60m by end of 2026; FY25 revenue growth +20% | FY25 revenue +4% (missed) |
| Feb 2025 | FY25 revenue growth ~10%; recurring growth 12–14%; ARR growth +20%; operating breakeven by end FY25 | Revenue +4%, recurring +7%, ARR +15%, operating profit positive (mostly missed) |
| Aug 2025 | Confidence in medium-term A$60m ARR; improved FY26 financial performance | FY26 operating profit halved; ARR ~A$27m |
| Feb 2026 | Accelerated double-digit ARR growth for FY26 | Withdrawn 5 May 2026 |
| Aug 2026 | FY27: increased recurring revenue growth, cost growth below revenue growth, improved operating profit | Pending |
Analyst note: The A$60m ARR end-2026 target is not referenced in FY26 materials and is effectively unattainable (FY26 ARR ~A$27m). A formal withdrawal was not located; treat the target as abandoned. Management credibility on guidance is weak: four consecutive guidance resets since FY24.
Products & Services
Diagnostics
| Product | Description | Capabilities / metrics | Target customer | Launch / version | Pricing model |
|---|---|---|---|---|---|
| RippleDown Expert | Rules engine based on Multiple Classification Ripple-Down Rules (MCRDR). Lab scientists and pathologists build and refine interpretive rules case by case without programmers | Automates up to ~90% of reporting in client labs; >100m cases interpreted a year; deployed in >25 countries for >25 years | Pathology laboratories (public and private), NHS trusts, international lab groups | Commercialised from the late 1990s; current version year not disclosed | Licence plus usage (per-interpretation) or fixed periodic fee; partner revenue share via Abbott |
| RippleDown Auditor | Rules-based auditing of data and results (e.g., test utilisation, data quality, compliance alerts) | Automates repeatable non-clinical checks in labs and hospitals | Laboratories, hospitals | — | Subscription / usage |
| Abbott co-sell / licence (AlinIQ ecosystem) | RippleDown distributed and co-sold by Abbott globally under the November 2019 licence and distribution agreement | FY25 Abbott revenue up 50% from licences and co-sales; global-partner revenue A$2.3m in FY26 | Abbott laboratory customers worldwide | Nov 2019 | Licence plus revenue share ("Tier 2" co-sale contracts) |
Coding & Data Quality Assurance
| Product | Description | Capabilities / metrics | Target customer | Launch / version | Pricing model |
|---|---|---|---|---|---|
| PICQ | Performance Indicators for Coding Quality. Automated, rules-based audit of coded admitted-patient episodes against ICD-10-AM/ACHI/ACS standards, flagging errors and missed complexity | Audited ~8m episodes from 362 sites in the last FY (>70% of ANZ admissions); deployed in Australia, NZ, Ireland, Canada, Saudi Arabia | Hospitals, health districts, health insurers/payers (e.g., Saudi CNHI) | Acquired with Pavilion Health 2020 (originated earlier); acquired code base superseded by internally developed functionality, with A$1.02m acquired-software impairment in FY26 | Subscription, indicatively ~A$1 per coded episode (FY25 investor presentation) |
| PICQ Audit | Module combining PICQ analytics with structured audit methodology and services to recover missed clinical complexity and funding | >20 clients and >A$1m ARR within nine months; about one-third of PICQ customers signed; management cites ~A$4m funding uplift a year per client | Australian local health districts and hospitals | FY25 | Subscription / programme fee |
| RISQ | Risk-adjusted data-quality and coding indicators tool (e.g., hospital-acquired complications, sentinel events) | Part of the coding-quality suite alongside PICQ | Hospitals, safety and quality units | Acquired with Pavilion 2020 | Subscription |
| Autonomous Coding Solution (ACS) | "No-touch" AI coding that assigns codes and groups episodes without human intervention for a subset of cases | Three programmes underway in FY25 (Australia, UK, Canada) generating A$0.6m; launching with selected customers in FY27 | Hospitals and health systems with coder shortages | Pilots FY25–FY26; commercial launch FY27 | Indicatively ~6–8x current coding-product pricing per episode (FY25 presentation) |
| Integrated Coding Platform (ICP) | End-to-end assisted-coding workbench supporting human coders; co-developed with Lean Business Services for Saudi Arabia | Implementation underway in a large Saudi hospital cluster (FY25); further development ceased in FY26 pending product/market fit, with capitalised software impaired | Saudi hospital clusters, later global | 2024–2025 | Indicatively ~2–3x current coding-product pricing |
| Autonomous Data Entry (ADE) | AI tool to automate structured data entry, using the existing customer base | Being launched with selected customers in FY27 | Existing hospital customers | FY27 (planned) | — |
| Coding audit and advisory services | Data-quality audits, coding assurance and on-site coding support (e.g., Singapore MOH A$1m, Fakeeh A$2m) | Delivered remotely and on-site | Ministries of health, insurers, hospital groups | Ongoing | Project / time-based (non-recurring) |
Knowledge Networks / Analytics
| Product | Description | Capabilities / metrics | Target customer | Launch / version | Pricing model |
|---|---|---|---|---|---|
| The Health Roundtable (HRT) platform | Beamtree is the full-service operator for The Health Roundtable Ltd, a not-for-profit ANZ benchmarking and improvement cooperative. It supplies data collection, standardisation, dashboards and peer benchmarking | 189 member hospitals; ~176,000 dashboard interactions a year; >10,000 unique benchmarks; covers ~80% of acute activity in ANZ; contract to July 2031 | Public and private hospitals (ANZ), formerly Abu Dhabi SEHA | Operated since acquisition of Potential(x) (Sep 2021); legacy software migrated off old cloud infrastructure in FY26 | Long-term operator contract (recurring); HRT is the company's largest customer |
| Evolve (UK) | Next-generation analytics and benchmarking collaborative for the NHS, built with the NHS Confederation | A$2m invested in 1H FY26 | NHS trusts and integrated care boards | Agreement FY25; build FY26 | Membership / subscription (terms not disclosed) |
| Global Health Comparators (GHC) | International comparator programme launched in 2021, incorporating the Global Health Data@Work initiative | Status not reported in recent filings | International health systems | 2,021 | — |
| Ability Roundtable | Benchmarking network for disability service providers (established 2013) | Exited in FY26 | Disability providers | — | Exited |
| Wellness / Aged Care Roundtable | Benchmarking network for aged-care and wellness providers | Exited in FY26 | Aged-care providers | — | Exited |
Clinical Decision Support (discontinued)
| Product | Description | Status |
|---|---|---|
| Ainsoff Deterioration Index (ADI) | Machine-learning early-warning score for in-hospital patient deterioration, acquired with Ainsoff (2021); Gold Coast Health collaboration (FY23) | Being wound down in consultation with affected customers; platform impaired in FY26 |
Financial Narrative
Basis: Statutory figures from Appendix 4E / Annual Reports (FY22, FY23, FY26) and management-format P&L from the FY25 and FY26 investor presentations. "Operating profit" is Beamtree's management measure (revenue less people and non-people operating costs, before non-operating items, D&A, impairment and interest). It works as an underlying cash EBITDA. "Reported EBITDA" is after non-operating items such as share-based payments, FX, restructuring costs and AASB 16 adjustments.
Income statement: notes and sources
Notes: (a) FY26 ARR is not given as a single headline figure. The FY26 presentation reports "underlying ARR" of A$25.4m, which excludes A$1.7m of discontinued products; this implies total ARR of about A$27.1m. ARR was A$28.0m in February 2026 (1H FY26 presentation). (b) FY22 recurring revenue is A$14.2m as restated in the FY23 Appendix 4E; the FY22 Appendix 4E showed licence/subscription fees of A$11.9m. (c) FY23 recurring revenue is A$21.2m in the FY25 presentation versus A$21.6m "licence, subscription and usage fees" in the FY23 Appendix 4E. (d) FY21 statutory revenue was A$8.4m with NPAT of A$-0.4m and operating profit of A$0.9m (FY22 Appendix 4E). The FY21 results release cited A$8.9m revenue, probably a pro-forma or total-income figure (discrepancy noted). (e) FY22 operating loss of A$4.0m includes about A$4.5m of growth investment (FY22 presentation).
Margins and growth (%)
Revenue CAGR: FY21–FY26 (5-year) 28.3% a year, mostly acquisition-driven (A$8.4m → A$29.2m). FY23–FY26 (3-year, organic) 8.6% a year. FY25–FY26 2.1%.
Trend commentary:
Growth has decelerated sharply: The 97% jump in FY22 reflected the Potential(x) and Ainsoff acquisitions. FY23's 38% included a full year of Potential(x) plus strong RippleDown and international wins. Since FY24, organic growth has slowed to 2–4% in total revenue, although recurring revenue has held at 7–10%. The non-recurring line swings with large one-off audits (Saudi national audit in FY24/FY25) and was deliberately de-emphasised in FY26.
Cost discipline has improved but not produced scale profits: Operating expenses grew 18% in FY23, then 12%, 2% and 3%. Operating profit turned positive in FY24 but peaked at only A$0.7m (FY25). FY26 fell back to A$0.4m as people costs rose 5% against 2% revenue growth.
Statutory losses are structural, not cyclical: D&A of A$5–5.5m a year (much of it amortisation of acquired customer lists and capitalised development) keeps the company loss-making at the statutory level even when operating cash flow is positive. FY26 adds A$13.1m of non-cash impairment. Customer-list amortisation (A$1.4m a year) is now largely complete (A$0.35m remaining), and the impaired asset base will lower FY27 amortisation, which should narrow statutory losses mechanically.
Balance sheet
Commentary: The balance sheet has steadily weakened. Cash fell from A$8.8m (FY23, after a A$4.7m equity raise) to A$2.5m (FY26), with the gap funded by NZ$4.0m (A$3.3m) of BNZ debt. FY26 working capital is negative (A$-4.8m) for two reasons. First, the BNZ loan was reclassified as current after the 30 June 2026 covenant breach; directors expect it to return to non-current at 31 December 2026 if the amended covenants are met. Second, deferred revenue rose to A$4.6m. Deferred revenue is non-cash and unwinds through service delivery, so underlying liquidity is better than the headline ratio suggests. Equity fell 44% in FY26, mainly from the impairment. Net tangible assets per share are now negative (-1.51 cents).
Debt facility (FY26 AR, Note 1): BNZ Customised Average Rate Loan; limit NZ$7.5m; maturity 3 March 2028; drawn NZ$4.0m (A$3.288m); undrawn NZ$3.5m (~A$3.0m). Borrower is Beamtree New Zealand Limited, accessible group-wide via intercompany loans. Covenants since 20 August 2026: minimum quarterly total revenue and cumulative cash operating profit (as a percentage of the FY27 budget, first tested 30 September 2026) plus minimum liquidity at all times. The FY25 presentation described an undrawn facility of NZ$5m, which suggests the limit or draw profile changed during the period (not reconciled in filings reviewed).
Cash flow
Commentary: Beamtree has never produced positive free cash flow after capitalised development in the period reviewed. Cumulative FY23–FY26 FCF is about A$-11.2m, funded by equity (~A$5.8m), debt (~A$2.8m net) and cash drawdown. FY26 capitalised development rose to A$3.7m (12.8% of revenue), including roughly A$2m for the UK Evolve platform. At the FY26 burn rate (~A$3m FCF deficit) and with A$5.5m of total liquidity, the company has about 18 months of runway without improvement. That makes the FY27 cost and revenue covenants, and the new CEO's capital allocation, the central monitorables.
Ratios
Cash conversion cycle: not meaningful. Beamtree holds no inventory, and payables days are not disclosed separately. DSO is shown as the relevant working-capital indicator. Ratios in years with negative EBITDA or net cash are left blank as not meaningful.
Inflections: (1) FY24 was the first year of positive operating profit. (2) FY26 is the first year with net debt, below-1x current ratio and a covenant breach. (3) The rise in asset turnover is driven by write-downs, not efficiency.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Contents | Key products | Status |
|---|---|---|---|
Diagnostics (Diagnostic Technology) | Expert-rules automation for pathology and diagnostic services | RippleDown Expert, RippleDown Auditor; Abbott co-sell | Core — continuing |
Coding & Data Quality Assurance | Coding audit, assurance and automation for hospital episodes | PICQ, PICQ Audit, RISQ, ACS, ICP | Core — continuing; ICP development paused |
Knowledge Networks (Analytics) | Benchmarking cooperatives and analytics platforms | Health Roundtable, Evolve (UK), formerly Ability and Wellness/Aged Care Roundtables | Core (Health Roundtable, Evolve); Ability and Wellness exited FY26 |
Clinical Decision Support | Clinical deterioration AI (Ainsoff Deterioration Index) and related tools | ADI | Discontinued / wind-down FY26 |
Segment recurring revenue (AUD Mn)
| Segment recurring revenue (AUD Mn) | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
Knowledge Networks / Analytics | 10.1 | 10.8 | 11.1 | 12.2 |
Diagnostics | 6.0 | 6.8 | 7.5 | 7.9 |
Coding & Data Quality Assurance | 4.4 | 5.3 | 5.9 | 7.2 |
Clinical Decision Support | 0.6 | 0.4 | 0.5 | 0.3 |
Total recurring revenue | 21.2 | 23.3 | 25.0 | 27.5 |
Segment recurring revenue growth (%)
| Segment recurring revenue growth (%) | FY24 | FY25 | FY26 |
|---|---|---|---|
Knowledge Networks / Analytics | 6.9 | 2.8 | 9.9 |
Diagnostics | 13.3 | 10.3 | 5.3 |
Coding & Data Quality Assurance | 20.5 | 11.3 | 22.0 |
Clinical Decision Support | -33.3 | 25.0 | -40.0 |
Total recurring revenue | 9.9 | 7.3 | 10.0 |
Segment total operating revenue (AUD Mn)
| Segment total operating revenue (AUD Mn) | FY25 | FY26 |
|---|---|---|
Diagnostics | 7.507 | 7.928 |
Coding & Data Quality Assurance | 9.352 | 8.783 |
Clinical Decision Support | 0.453 | 0.310 |
Knowledge Networks | 11.286 | 12.171 |
Group total | 28.598 | 29.192 |
Segment share of total revenue (%)
| Segment share of total revenue (%) | FY25 | FY26 |
|---|---|---|
Diagnostics | 26.3 | 27.2 |
Coding & Data Quality Assurance | 32.7 | 30.1 |
Clinical Decision Support | 1.6 | 1.1 |
Knowledge Networks | 39.5 | 41.7 |
Income statement metric (AUD Mn)
| Income statement metric (AUD Mn) | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
Total revenue | 16.5 | 22.8 | 27.6 | 28.6 | 29.2 |
Recurring revenue | 14.2 | 21.2 | 23.3 | 25.0 | 27.5 |
Non-recurring revenue | 2.3 | 1.6 | 4.3 | 3.6 | 1.6 |
Annual recurring revenue at year end (ARR) | 18.2 | 22.8 | 25.5 | 29.2 | — |
People expenses | 14.2 | 17.3 | 19.7 | 20.6 | 21.5 |
Non-people operating expenses | 6.3 | 6.9 | 7.5 | 7.3 | 7.3 |
Total operating expenses | 20.6 | 24.2 | 27.2 | 27.9 | 28.8 |
Operating profit (management measure) | -4.0 | -1.4 | 0.4 | 0.7 | 0.4 |
Reported EBITDA | — | -1.2 | -0.5 | -0.7 | 0.3 |
Depreciation & amortisation | — | 4.9 | 5.4 | 5.5 | 5.1 |
Impairment (goodwill and software) | 0 | 0 | 0 | 0 | 13.1 |
Pre-tax income | -6.0 | -6.2 | -5.8 | -6.4 | -18.2 |
Net income (NPAT) | -4.4 | -6.9 | -5.1 | -6.2 | -18.3 |
Basic EPS (A cents) | — | -2.80 | -1.81 | -2.13 | -6.30 |
Diluted EPS (A cents) | — | -2.80 | -1.81 | -2.13 | -6.30 |
Dividends per share (A cents) | 0 | 0 | 0 | 0 | 0 |
Margin / growth metric (%)
| Margin / growth metric (%) | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
Revenue growth | 97.3 | 37.6 | 21.2 | 3.6 | 2.1 |
Recurring revenue growth | — | 49.3 | 9.9 | 7.3 | 10.0 |
Recurring share of revenue | 86.1 | 93.0 | 84.4 | 87.4 | 94.4 |
Operating profit margin (management) | -24.2 | -6.1 | 1.4 | 2.5 | 1.2 |
Reported EBITDA margin | — | -5.4 | -1.7 | -2.3 | 1.1 |
Net margin | -26.9 | -30.3 | -18.5 | -21.5 | -62.6 |
Balance Sheet
| Balance sheet metric (AUD Mn) | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
Total assets | — | 62.5 | 59.6 | 54.3 | 37.4 |
Cash & equivalents | 6.3 | 8.8 | 5.0 | 4.8 | 2.5 |
Trade & other receivables | — | 5.3 | 6.3 | 4.7 | 5.2 |
Total current assets | — | 14.4 | 11.5 | 9.6 | 8.0 |
Intangibles incl. goodwill | — | 45.7 | 44.7 | 41.8 | 27.8 |
Goodwill | — | — | 30.9 | 30.9 | 21.4 |
Short-term borrowings | — | 0 | 0 | 0 | 3.3 |
Long-term borrowings (bank debt and investment bond) | — | 0.5 | 0.5 | 2.3 | 0 |
Total borrowings (excl. leases) | — | 0.5 | 0.5 | 2.3 | 3.3 |
Lease liabilities | — | 0.2 | 1.1 | 1.0 | 0.7 |
Net debt (borrowings less cash; negative = net cash) | — | -8.3 | -4.5 | -2.5 | 0.8 |
Contract liabilities (deferred revenue) | — | 3.1 | 4.1 | 2.8 | 4.6 |
Total current liabilities | — | 12.2 | 9.0 | 7.8 | 12.8 |
Working capital (current assets less current liabilities) | — | 2.2 | 2.5 | 1.8 | -4.8 |
Total equity | — | 47.2 | 47.1 | 41.9 | 23.4 |
Cash flow metric (AUD Mn)
| Cash flow metric (AUD Mn) | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
Receipts from customers (incl. GST) | — | 25.4 | 30.9 | 31.7 | 33.1 |
Operating cash flow | — | 0.8 | -0.5 | 0.6 | 0.9 |
Capex: PP&E | — | 0.1 | 0.1 | 0.2 | 0.2 |
Capex: capitalised development (intangibles) | — | 2.5 | 4.0 | 2.3 | 3.7 |
Total capex | — | 2.6 | 4.1 | 2.5 | 3.9 |
Free cash flow (OCF less total capex) | — | -1.8 | -4.6 | -1.8 | -3.0 |
Equity raised (shares and options) | — | 4.7 | 1.0 | 0.1 | 0 |
Net debt drawn / (repaid) | — | 0 | 0 | 1.8 | 1.0 |
Dividends paid | 0 | 0 | 0 | 0 | 0 |
Share buybacks | 0 | 0 | 0 | 0 | 0 |
Closing cash | 6.3 | 8.8 | 5.0 | 4.8 | 2.5 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
ROE (% NPAT / year-end equity) | -14.6 | -10.8 | -14.7 | -78.2 |
ROA (% NPAT / year-end total assets) | -11.1 | -8.6 | -11.3 | -48.9 |
ROIC (% pre-tax EBIT / (equity + borrowings + leases), year-end) | -12.9 | -12.0 | -14.0 | -66.6 |
ROIC ex-impairment FY26 (%) | — | — | — | -18.5 |
Current ratio (x) | 1.18 | 1.28 | 1.23 | 0.62 |
Debt / equity (x, borrowings excl. leases) | 0.01 | 0.01 | 0.05 | 0.14 |
Net debt / reported EBITDA (x) | — | — | — | 2.5 |
Reported EBITDA / interest expense (x) | — | — | — | 1.3 |
Operating profit / interest expense (x) | — | — | 4.3 | 1.5 |
Asset turnover (x, revenue / year-end assets) | 0.36 | 0.46 | 0.53 | 0.78 |
Days sales outstanding (trade receivables / revenue × 365) | — | — | 43 | 50 |
Revenue by region (AUD Mn)
| Revenue by region (AUD Mn) | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
Australia | 4.8 | 12.4 | 15.5 | 16.9 | 15.7 | 17.3 |
International (incl. NZ, Europe, Middle East, Asia, Americas) | 3.6 | 4.1 | 7.3 | 10.7 | 12.9 | 11.9 |
Group total | 8.4 | 16.5 | 22.8 | 27.6 | 28.6 | 29.2 |
Revenue growth by region (%)
| Revenue growth by region (%) | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
Australia | 158.3 | 25.0 | 9.0 | -7.1 | 9.8 |
International | 13.9 | 78.0 | 46.6 | 20.6 | -7.4 |
Region revenue (AUD Mn)
| Region revenue (AUD Mn) | FY25 | FY26 |
|---|---|---|
Australia — recurring | 15.512 | 17.267 |
Australia — non-recurring | 0.229 | 0.015 |
Europe — recurring | 1.858 | 2.067 |
Europe — non-recurring | 0 | 0 |
Rest of world — recurring | 7.652 | 8.214 |
Rest of world — non-recurring | 3.347 | 1.629 |
Total | 28.598 | 29.192 |
Recurring revenue by market (AUD Mn)
| Recurring revenue by market (AUD Mn) | FY25 | FY26 |
|---|---|---|
Australia & New Zealand | 17.9 | 20.0 |
International | 7.1 | 7.6 |
Share price metric
| Share price metric | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
Share price at 30 June (AUD) | 0.24 | 0.23 | 0.25 | 0.14 |
Annual change (%) | -20 | -4 | 9 | -44 |
Valuation Multiples
| Multiple | Beamtree | Comment |
|---|---|---|
Market capitalisation (AUD Mn) | ~36.6 to 38 | Stocklight snapshot A$36.6m |
Enterprise value (AUD Mn) | ~38 | Plus A$3.3m debt and A$0.7m leases, less A$2.5m cash |
EV / Sales FY26 (x) | ~1.3 | On A$29.2m revenue |
EV / ARR (x) | ~1.4 | On ~A$27m implied ARR |
EV / Reported EBITDA FY26 (x) | n.m. (~120x) | EBITDA A$0.31m |
P/B (x) | ~1.6 | Book equity A$23.4m; negative NTA |
Debt instrument
| Debt instrument | Amount | Maturity | Terms |
|---|---|---|---|
BNZ Customised Average Rate Loan | NZ$4.0m drawn (A$3.288m) of NZ$7.5m limit | 3 Mar 2028 | Quarterly revenue and cash-operating-profit covenants plus minimum liquidity (from 20 Aug 2026); classified current at FY26 pending covenant compliance |
Lease liabilities (North Sydney office) | A$0.747m (A$0.232m current) | Over remaining lease term | AASB 16 |
Investment bond | A$0 (A$0.537m repaid in FY25) | Repaid | — |
Raise by Date
| Date | Raise | Detail |
|---|---|---|
Jun 2019 | IPO on ASX | — |
May 2020 | Placement linked to the Pavilion acquisition | — |
Feb–Mar 2021 | A$12m firm commitments | Placement to fund growth and acquisitions; Mirrabooka became a substantial holder |
FY23 | A$4.7m share issue | Equity raise |
FY24 | A$1.0m options and share proceeds | Option exercises |
Analyst Conclusions
Management guidance (FY27)
Management has not given quantitative revenue, ARR or earnings guidance for FY27. The qualitative guidance in the FY26 Annual Report and presentation is:
-
Increased recurring revenue growth versus FY26 (+10%), with a rising share from international markets (UK, Canada, Saudi Arabia).
-
Cost growth below revenue growth.
-
Continued improvement in operating profit.
-
Launch of ACS and ADE with selected customers.
-
Focus on Diagnostics, Coding and Analytics.
Consensus expectations
No reliable current consensus is available. The only third-party view is a single stale target (A$0.60, pre-FY26 results). Simply Wall St's August 2025 summary cited forecast revenue growth of about 20% a year over three years, which looks inconsistent with delivered results.
Bull case
-
Embedded, recurring franchise at a distressed multiple. About A$27m of 94%-recurring, low-churn revenue, anchored by a contract to 2031, trades at roughly 1.3–1.4x EV/Sales. That is a low price for vertical health software with this retention profile, and the register (Jakeco 10.4%, Chair ~10%, Crescent 5%) is concentrated enough to support corporate activity.
-
Operating leverage plus a cleaner P&L. The FY26 write-downs and completed customer-list amortisation should cut D&A materially. If recurring growth of 10% continues with cost growth held below it, operating profit could rise from A$0.4m toward A$2–3m within two years, and statutory losses could narrow sharply.
-
Autonomous coding optionality under proven SaaS leadership. ACS pricing of 6–8x current per-episode rates, sold into a base that audits more than 70% of ANZ admissions, offers asymmetric upside. The new CEO and a TechnologyOne director bring direct experience of scaling Australian enterprise software into the UK.
Bear case
-
Growth has structurally stalled. Total revenue grew 3.6% and 2.1% in the last two years. International revenue fell 7% in FY26. The A$60m ARR goal was missed by more than half, and impairment testing already assumes CAGRs of 7–13% that the business has not recently delivered, so further goodwill impairment (A$21.4m remaining) is plausible.
-
Liquidity and covenant squeeze. With A$2.5m cash, A$5.5m total liquidity, a ~A$3m annual FCF deficit and new quarterly covenants tied to the FY27 budget, one missed quarter could force a dilutive raise at A$0.10–0.15 a share, or lender-driven restrictions.
-
Execution and leadership risk. Three CEOs in 18 months, two CFO exits in 10 months, a pattern of guidance misses, abandoned AI products (ADI, paused ICP) and inconsistencies in the FY26 disclosures all point to execution capability that a new CEO must rebuild while competing against much better-funded AI coding entrants.
Catalysts and monitorables (next 12 months)
| Timing | Catalyst / monitorable |
|---|---|
| Late Oct 2026 | Q1 FY27 trading update and first amended-covenant test (30 Sep 2026): revenue and cash operating profit vs FY27 budget |
| 26 Nov 2026 | AGM: CEO strategy presentation, LR 10.14 equity approvals, possible new CFO announcement |
| Dec 2026 | End of Stepniak's Head of International commitment; international pipeline conversion (UK, Canada, Saudi) |
| Feb 2027 | 1H FY27 results: debt reclassification to non-current, ARR trajectory, D&A step-down, cash balance |
| FY27 | ACS and ADE first commercial contracts and pricing; Evolve UK paying members; Fakeeh renewal (contract ends ~May 2027) |
| Ongoing | Equity raising risk; register changes (Jakeco, Crescent); any corporate approach following the strategic review's "corporate options" scope |
| Aug 2027 | FY27 results and the first full-year test of the Pye strategy; further impairment risk |
Concluding analyst verdict
Beamtree, the former PKS Holdings, is a credible niche healthcare-data business inside a weak corporate shell. The product franchises are genuine. RippleDown has automated laboratory interpretation for a quarter of a century. PICQ is effectively the ANZ standard for coding-quality audit. The Health Roundtable is the region's benchmarking backbone with a contract running to 2031. Together they produce about A$27m of recurring revenue with low churn and modestly positive operating cash flow.
The corporate story built on these assets since 2020 has not worked. That story was a fast-growing, international, AI-led health-data platform targeting A$60m ARR by end-2026. Organic growth has slowed to low single digits. The 2021 AI acquisition (Ainsoff) has been abandoned. Goodwill from the Pavilion and Potential(x) deals has been cut by A$9.6m. The company breached its only growth covenant. It has churned through three CEOs and two CFOs in 18 months. Cash of A$2.5m against a recurring free-cash-flow deficit leaves little room for error under the new quarterly covenants.
FY26 is best read as a reset rather than a collapse. The impairments are non-cash. The product set has been pruned to its defensible core. Directors have switched fees to equity and insiders have been buying. The board has hired a CEO with directly relevant enterprise-SaaS experience. At roughly 1.3x EV/Sales, the market prices in little beyond the existing contracted base, so upside depends on two things: autonomous coding converting into paying contracts, and the company proving it can fund itself without heavy dilution.
Verdict: a high-risk, special-situation holding. The next two quarterly covenant tests and the first commercial ACS contracts will decide whether this becomes a re-rating story or a recapitalisation. Valuation support from strategic interest is the most plausible floor.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Prior roles / background | Remuneration |
|---|---|---|---|---|
Gareth Pye | Chief Executive Officer | From 13 Jul 2026 | 18+ years at TechnologyOne (ASX: TNE): CFO, Head of Strategy, Head of Product (Financials) | FY27 package: A$450k base salary, A$150k STI, A$100k share grant, A$250k LTI (ASX release, 15 Jun 2026) |
Marek Stepniak | Head of International (CEO Mar 2025 – Jul 2026; previously Chief Growth Officer) | Joined Jun 2023 | Led international pipeline in UK, Canada and Middle East | FY26 total A$481,459 (salary A$465,750; cash bonus A$40,000; super A$30,000; STI equity A$84,000; LTI reversal A$-181,840); FY25 total A$964,359 |
CFO | Vacant / not announced | — | Michelle Spiller (appointed 2 Feb 2026, resigned 24 Jul 2026); Mark McLellan (CFO/COO Apr 2022 – 10 Oct 2025) | Spiller FY26 total A$292,985; McLellan FY26 A$-139,959 (net of forfeited LTI) |
Maria Clemente | Company Secretary (outsourced, Automic Group) | Current | Former ASX senior listings adviser; restructuring lawyer | — |
“—” = not publicly disclosed.
Board of Directors
| Director | Role | Appointed | Background | Committees | Shareholding | FY26 remuneration (AUD) |
|---|---|---|---|---|---|---|
Emma Gray | Non-Executive Chair (Executive Chair 2 Mar – 31 Jul 2026) | 24 Nov 2022 | Ex-ANZ Group Executive Data & Automation and CDO; ex-Woolworths Group Executive (Loyalty, Data); ex-Bain partner (15 yrs); MBA Harvard; BA Dublin City University; NED of Bank of New Zealand | RemCo, ARC member | 29,530,333 shares (~10.2%) | 211,606 (NED A$80,359 + executive chair A$131,247) |
Prof. Andy Hardy | Non-Executive Director | 31 Mar 2025 | CEO University Hospitals Coventry & Warwickshire NHS Trust since 2010; Deputy Chair, NHS National Improvement Board | — | Nil | 61,392 (fee £31,200 p.a.) |
Michael Hill | Non-Executive Director | 31 May 2019 | Founder, MD and CIO of Bombora Special Investment Growth Fund; ex-Ironbridge partner; ex-EY partner; CA | RemCo, ARC member | 1,958,439 shares | 60,269 |
Stuart MacDonald | Non-Executive Director | 15 Oct 2025 | COO of TechnologyOne since 2017; ex-Infor; founded consultancy sold to UXC Red Rock (2014) | Chair RemCo (from 30 Jun 2026) | 200,000 shares | 43,116 |
Martin Bowles AO PSM | Non-Executive Director | 2 Mar 2026 | Ex-National CEO, Calvary Health Care; ex-Secretary, Department of Health; ex-Secretary, Department of Immigration and Border Protection | Chair ARC (from 1/30 Jun 2026) | 596,774 shares | 20,833 (equity) |
Bradley Lancken | Former NED (retired 30 Jun 2026) | 18 Oct 2019 | Managing Partner, Liverpool Partners; ex-Archer Capital, Seven Group | Former Chair RemCo | 3,000,000 shares | 70,314 |
James (Jim) Birch AM | Former NED (retired 30 Jun 2026) | 14 Mar 2021 | Ex-Chair ADHA; ex-Deputy Chair IHPA; Chair of Calvary and Lifeblood | Former Chair ARC | 366,939 shares | 69,455 |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
15 Oct 2024 / Mar 2025 | Tim Kelsey steps down as CEO after 4+ years; becomes senior advisor and Global Impact Committee chair | Planned transition after the international pivot |
12 Mar 2025 | Marek Stepniak appointed CEO | Internal promotion from Chief Growth Officer |
10 Oct 2025 | CFO/COO Mark McLellan resigns | Announced alongside FY25 results |
2 Feb 2026 | Michelle Spiller appointed CFO | — |
2 Mar 2026 | Emma Gray becomes Executive Chair (time-limited, A$30k a month) to run the strategic review | CEO refocused on international markets |
15 Jun 2026 | Gareth Pye appointed CEO (effective 13 Jul 2026); Stepniak becomes Head of International until at least end-2026 | Outcome of an international search |
30 Jun 2026 | Birch and Lancken retire | Board renewal |
24 Jul 2026 | CFO Spiller resigns; 3m performance rights lapse | Second CFO exit in 10 months |
1 Aug 2026 | Gray returns to Non-Executive Chair | — |
Major Shareholders
| Holder | Shares | % | Date of last notice / source |
|---|---|---|---|
Jakeco Pty Ltd | 30,195,924 | 10.40 | 6 Mar 2026 (Market Index) |
Emma Gray (Invia Custodian ATF Arrakis Family Trust; Arrakis Nominees) | 29,530,333 | ~10.2 | FY26 AR |
Crescent Capital Partners Holdings Pty Ltd | 14,672,420 | 5.05 | 5 May 2026 (Market Index) |
Bombora Investment Management | 18,600,000 (historic) | 8.63 (Feb 2021) | — |
Mirrabooka Investments | 9,673,818 (historic) | 5.16 (Feb 2021) | — |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Positioning vs. Beamtree |
|---|---|---|
Diagnostics (lab interpretation and middleware) | Data Innovations (Instrument Manager; Roper Technologies) | Dominant lab middleware with auto-verification rules; broader instrument connectivity |
Diagnostics | Clinisys (lab information systems) | LIS-embedded rules and decision support; owns the LIS layer |
Diagnostics | Siemens Healthineers (Atellica Data Manager), Beckman Coulter (DxONE / REMISOL), Roche (navify / infinity) | Instrument vendors bundling data-management and auto-validation software |
Diagnostics | Abbott (AlinIQ) | Partner and channel, but also controls the customer relationship (co-opetition) |
Coding & DQA | Solventum (formerly 3M Health Information Systems) | Global leader in computer-assisted coding and coding audit; much larger scale |
Coding & DQA | Optum (computer-assisted coding / revenue cycle) | US-centric, large-scale coding automation |
Coding & DQA | Autonomous-coding specialists such as Fathom, Nym Health, CodaMetrix, AKASA | Venture-backed AI-native coding automation, mostly US-focused; direct competitors to ACS |
Coding & DQA | EMR vendors (Oracle Health, Epic, InterSystems TrakCare in ANZ) | Native coding modules inside the EMR |
Analytics & benchmarking | Alcidion (ASX: ALC) | ANZ/UK health informatics (Miya Precision, Kyra patient flow); adjacent rather than direct |
Analytics & benchmarking | Health Catalyst, Premier Inc., Vizient | US benchmarking and analytics |
Analytics & benchmarking | UK benchmarking providers (e.g., CHKS, Model Health System / NHS internal tools) | Competing approaches to NHS benchmarking against Evolve |
Peer Comparison FY2026
| Metric | Beamtree (BMT) | Alcidion (ALC) |
|---|---|---|
FY26 revenue (AUD Mn) | 29.2 | 51.6 |
Revenue growth (%) | 2 | 27 |
ARR (AUD Mn) | ~27 (underlying 25.4) | 38.3 (+34%) |
Underlying EBITDA margin (%) | 1.2 (operating profit) | 13.2 |
NPAT (AUD Mn) | -18.3 | 2.3 |
Capitalised R&D / revenue (%) | 12.8 | 0 (no R&D capitalised in FY26) |
Net cash / (debt) (AUD Mn) | -0.8 | 20.6 |



